|
|
|
|
| LEADER |
02616nmm a2200565 u 4500 |
| 001 |
EB002166244 |
| 003 |
EBX01000000000000001304023 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230607 ||| eng |
| 020 |
|
|
|a 9780841233966
|
| 050 |
|
4 |
|a RM301.25
|
| 100 |
1 |
|
|a Abdel-Magid, Ahmed F.
|e [editor]
|
| 245 |
0 |
0 |
|a Complete accounts of integrated drug discovery and development: Volume 1
|b recent examples from the pharmaceutical industry
|c Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea, Alabama, United States, Jaan A. Pesti, editor, EnginZyme AB, Stockholm, Sweden, Rajappa Vaidyanathan, editor, Bristol-Myers Squibb, Bangalore, India ; sponsored by the ACS Division of Organic Chemistry
|
| 260 |
|
|
|a Washington, DC
|b American Chemical Society
|c 2018, 2018
|
| 300 |
|
|
|a 314 pages
|b illustrations (some color)
|
| 505 |
0 |
|
|a Includes bibliographical references and index
|
| 653 |
|
|
|a Membrane proteins / Chemical inhibitors / Development
|
| 653 |
|
|
|a MEDICAL / Pharmacology / bisacsh
|
| 653 |
|
|
|a Drug Discovery
|
| 653 |
|
|
|a MEDICAL / Research / bisacsh
|
| 653 |
|
|
|a Drug Development
|
| 653 |
|
|
|a Glucokinase / Regulation / Development
|
| 653 |
|
|
|a Pharmaceutical industry
|
| 653 |
|
|
|a Oxazepines
|
| 653 |
|
|
|a Alzheimer's disease / Treatment / Technological innovations
|
| 653 |
|
|
|a Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
|
| 653 |
|
|
|a Rapamycin / Chemical inhibitors / Development
|
| 653 |
|
|
|a Protein kinases / Chemical inhibitors / Development
|
| 653 |
|
|
|a TOR Serine-Threonine Kinases / antagonists & inhibitors
|
| 653 |
|
|
|a Fibrinolysis
|
| 653 |
|
|
|a Drug development
|
| 653 |
|
|
|a Alzheimer Disease / drug therapy
|
| 653 |
|
|
|a Hepatitis C virus / Treatment / Technological innovations
|
| 653 |
|
|
|a Fibrinolysis / Chemical inhibitors / Development
|
| 653 |
|
|
|a G proteins / Antagonists / Development
|
| 653 |
|
|
|a Hepacivirus
|
| 653 |
|
|
|a Glucokinase
|
| 653 |
|
|
|a Purines / Receptors / Antagonists / Development
|
| 653 |
|
|
|a Amyloid Precursor Protein Secretases / antagonists & inhibitors
|
| 653 |
|
|
|a Pharmaceutical technology
|
| 700 |
1 |
|
|a Pesti, Jaan A.
|e [editor]
|
| 700 |
1 |
|
|a Vaidyanathan, Rajappa
|e [editor]
|
| 710 |
2 |
|
|a American Chemical Society
|b Division of Organic Chemistry
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b ACS
|a ACS Symposium Series
|
| 490 |
0 |
|
|a ACS symposium series
|
| 500 |
|
|
|a Distributed in print by Oxford University Press
|
| 856 |
4 |
0 |
|u https://pubs.acs.org/doi/book/10.1021/bk-2018-1307
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615.1/9
|